Abstract: Optimization and production of a spectacle lens for a specific wearing situation for correcting at least one astigmatic refraction of an eye of a spectacles wearer, which in a reference viewing direction of the eye has a cylinder reference value and a cylinder reference axis, comprising: specifying an object distance for at least one evaluation point of the spectacle lens; determining a transformed astigmatic refraction for the at least one evaluation point of the spectacle lens from the cylinder reference value and the cylinder reference axis depending on the specified object distance; and optimizing the spectacle lens such that for the at least one evaluation point a correction of the transformed astigmatic refraction by the spectacle lens in the specific wearing situation is taken into consideration, wherein determining the transformed astigmatic refraction comprises determining a transformed cylinder value and/or a transformed cylinder axis depending on the specified object distance.

Abstract: The present invention relates in summary to a method for checking and/or determining user data of a spectacle lens user comprising providing subjective data of a spectacle lens user, wherein the subjective data comprise at least subjective refraction data, providing objective refraction data of the spectacle lens user, comparing at least one subset of the subjective refraction data with at least one subset of the objective refraction data and determining a comparison result, matching at least the subset of the subjective refraction data to the objective refraction data on the basis of the comparison result under the assumption that the comparison result fulfills at least one predetermined comparison condition, otherwise maintaining at least the subset of the subjective refraction data and/or providing a message containing the comparison result, and to a further method, a computer program product and two devices for checking and/or determining user data.

Abstract: The present invention relates to compounds of formula I wherein R1a to R1e, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.

Abstract: The invention relates to a security label for identifying products comprising a layer comprising a shape memory polymer, wherein a surface profile comprising information for identifying the product is embossed in the layer and wherein the layer has a smooth surface in a first state and the layer has the embossed surface profile in a second state, wherein the security label is adapted such that the layer can be changed from the first or second state to the second or first state upon reading out the security label and to a connection means for connecting the layer to the product.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.

Abstract: The invention relates to a method for producing a progressive spectacle lens and to a corresponding apparatus, a computer program product, a storage medium and to the use of a progressive spectacle lens. The invention also relates to a method for producing a progressive spectacle lens for correcting defective vision of a spectacle wearer, comprising the following steps: the vertical and/or the horizontal spatial position of a distance reference point and/or a near reference point is specified or determined in accordance with individual data of the spectacle wearer; the spectacle lens is optimized or calculated such that the required dioptric effect of the spectacle lens is obtained in the individually determined distance reference point and/or the near reference point.

Abstract: The present invention relates to compounds of formula I wherein R1a to R1c, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

Abstract: The present invention relates to compounds of formula I wherein R1a to R1e, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Abstract: The invention relates particularly to a spectacle lens having a first and a second surface, wherein at least the first surface of the spectacle lens has a major portion zone and at least one prism zone. The major portion zone of the first surface, together with the opposing second surface of the spectacle lens, forms a major portion of the spectacle lens, which is designed for vision in at least a predetermined distance. The prism zone of the first surface, together with the opposing second surface of the spectacle lens, forms a prism portion, which is designed and arranged such that an optical image of a display is formed at a predetermined virtual distance in front of the eyes of the spectacle wearer. The invention further relates to spectacles, which comprise the spectacle lens, and to a method and apparatuses for calculating or optimizing and producing the spectacle lens.

Abstract: A transplant/implant device for delivering at least one predetermined biologically active compound to a human or animal host system or for another biological function in the host system is produced by genetically engineering vital chondrocytes or mixing chondrocytes with another type of native or genetically engineered cells or mixing chondrocytes with artificial particles having a size comparable to the size of cells or combining at least two of the named steps of engineering or mixing and by subjecting the chondrocytes or the mixture comprising the chondrocytes to three dimensional culture conditions for in vitro production of cartilaginous tissue whereby the cells and/or the artificial particles are immobilized in the cartilaginous tissue. The chondrocytes produce and maintain the cartilaginous tissue and the chondrocytes themselves or cells of another cell type immobilized in the cartilaginous tissue are able to produce and secrete the at least one predetermined compound.

Abstract: The present invention relates to compounds of formula I wherein R.sup.1a to R.sup.1e and R.sup.2 to R.sup.5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

Abstract: Disclosed is a rotor (1) for an electric rotor motor, consisting of a rotor bell (2) with a peripheral wall (4) and at least one one-sided rotor base (6) to enclose a stator, in particular as a part of a motor housing with a high IP rating, for example IP54 per DIN/IEC-EN 60034-5. The rotor bell (2) features a heat sink (12) with high heat conductivity that extends through the rotor base (6) in such a way that the motor heat arising on the inside can be removed via the heat sink (12) through the rotor base (6) to the outside into the environment. Further, the invention relates to an electric rotor motor, in particular with an encapsulated motor housing with a high IP-protection system, for example IP54 per DIN/IEC-EN 60034-5, consisting of a stator and a rotor (1) enclosing the stator in an embodiment of the above-described type.

Abstract: A method and device for calculating design parameters of a design of a progressive spectacle lens on the basis of a predetermined design polygon. The design parameters are calculated by specifying a point within the design polygon, in which the specified point defines the progressive spectacle lens design, and then determining a value of each design parameter at the specified point by an interpolation of at least part of the predetermined values at the corner points and, optionally, of at least part of the predetermined values of the design parameter at the at least one additional point.

Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Abstract: A module for a tester for the testing of circuit boards is described. Such testers have a basic grid on which an adapter and/or a translator may be arranged in order to connect contact points of the basic grid with circuit board test points of a circuit board to be tested. The module comprises a support plate and a contact board. The contact board is formed by a rigid circuit board section which is described as the basic grid element, and at least one flexible circuit board section. Provided on the basic grid element are contact points which each form part of the contact points of the basic grid. The basic grid element is mounted at an end face of the support plate, and the flexible circuit board section is bent in such a way that at least part of the other section of the contact board is parallel to the support plate.

Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5-C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2 represents hydrogen, C1-C4alkyl, or CF3; R3 represents hydrogen, C1-C4alkyl, or CF3; R4 represents a substituted or unsubstituted C5-C10 aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.

Abstract: The invention relates to a method for remote-control programming and to a machine control system 2 for performing the method. To refine the method so as to simplify and shorten an execution operation of a control program source yet automatically avoid version conflicts between the control program source and the compilate in the machine control system, it is proposed that the program source 3a stored in memory in the machine control system be executed by means of a programming device 1, and after the execution, the compilate of the executed program source is generated and stored in memory in the machine control system, where it is made available to a control module.

Abstract: The present invention relates to compounds of formula I wherein R1a to R1c, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.